Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
As GLP-1 receptor agonists continue expanding across obesity, diabetes, fatty liver disease, and cardiometabolic care, clinicians are increasingly confronting a pressing question: Does long-term use lead to tolerance, or do apparent diminishing returns reflect predictable physiology
In patients with DM2 the incretin response is diminished, but the insulinotropic effect of GLP-1 is conserved.28 Under normal conditions GLP-1 has a short half-life (approximately 2 min), as it is rapidly degraded by dipeptidylpeptidase 4, so GLP-1 analogues resistant to this enzyme have been developed for the treatment of DM2.29 arGLP-1: glucagon-like peptide 1 receptor agonist
However, more controlled studies are needed before drawing firm conclusions
Although there have been positive outcomes in lab tests, both peptides are research chemicals, with their effectiveness and patient safety in humans not fully proven
Victoza comes in three dose strengths: 0.6 mg, 1.2 mg, and 1.8 mg
US$ 29.71
US$ 24.06
US$ 23.36
US$ 25.32
US$ 24.54
US$ 27.70
US$ 27.53
